Home > Boards > US OTC > Biotechs > Fortress BioTechnology (FBIO)

i have never seen such an undervalued stock

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mrguitar Member Profile
 
Followed By 0
Posts 25
Boards Moderated 0
Alias Born 09/24/09
160x600 placeholder
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 11/4/2019 7:30:00 AM
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development GlobeNewswire Inc. - 10/28/2019 8:30:05 AM
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual ... GlobeNewswire Inc. - 10/18/2019 8:30:05 AM
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 8/14/2019 7:30:00 AM
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors GlobeNewswire Inc. - 8/1/2019 8:00:00 AM
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Manageme... GlobeNewswire Inc. - 6/3/2019 7:00:00 AM
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 5/13/2019 7:30:00 AM
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors GlobeNewswire Inc. - 4/30/2019 7:30:00 AM
Market Trends Toward New Normal in Colgate-Palmolive, Nucor, NeoPhotonics, Piper Jaffray Companies, The Ensign Group, and For... GlobeNewswire Inc. - 4/3/2019 8:45:00 AM
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 3/12/2019 7:30:00 AM
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary) GlobeNewswire Inc. - 2/11/2019 7:30:00 AM
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for th... GlobeNewswire Inc. - 12/19/2018 8:00:00 AM
mrguitar   Monday, 05/13/19 01:51:36 PM
Re: None
Post # of 57 
i have never seen such an undervalued stock as FBIO. Their stake in CKPT and MBIO is worth the total market value of fbio. If you go to their website you will see all of the other companies and subsidiaries that fbio owns or has a stake in. They own journey medical which had sales of 25 mil last year. That company alone is worth about 100 mil if they sold it.On top of that they have a potential deal for atxi which they own 40% .They also have a potential deal with caelum biosciences another subsidiary. FBIO should have a market cap of at least 400 mil not 100 mil.People just dont do their due diligence they just chase momentum.


Michael Spector, President and Chief Executive Officer of Caelum, said, “CAEL-101 appears to have a unique capability of binding to both kappa and lambda misfolded proteins. Data from the Phase 1a/1b study indicate that CAEL-101 is a well-tolerated therapy that leads to a rapid and clinically relevant organ response, particularly in the heart and kidneys. Further, CAEL-101 showed a statistically significant improvement from baseline in global longitudinal strain, an endpoint that has been correlated with survival in patients with AL amyloidosis. We are very pleased to collaborate with Alexion, a global leader in the rare disease field.”

Under the terms of the agreement, Alexion will acquire a minority equity interest in Caelum and an exclusive option to acquire the remaining equity in the company based on Phase 2 data for pre-negotiated economics. Alexion will make payments to Caelum totaling up to $60 million, including the purchase price for the equity and milestone-dependent development funding payments. The collaboration also provides for potential additional payments of up to $500 million, including the upfront and regulatory and commercial milestone payments, in the event Alexion exercises the acquisition option. The collaboration will leverage Alexion’s expertise in rare disease antibody development and commercial franchise in hematology. Alexion and Caelum will collaborate on the design of the ongoing development program for CAEL-101. Caelum will be responsible for conducting the development program through the end of Phase 2 and for manufacturing CAEL-101.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist